Next Steps for Everolimus in Metastatic Breast Cancer OncLive To explore this further, the phase II BOLERO-4 trial is examining everolimus plus letrozole as first-line therapy in ER-positive, HER2-negative metastatic breast cancer, adds Hope S. Rugo, MD. A leading concern with the administration of ... 20 mg of ... |
